Lina Zhao

Dr. Lina Zhao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Diabetes
Verified
Journal Article
Closed access
PDF file
RHRong Huang
Rong Huang
XBXinxiu Bai
Xinxiu Bai
XLXueyan Li
Xueyan Li
XWXiaohui Wang
Xiaohui Wang
LZLina Zhao
Lina Zhao
Pancreatic β-cell dysfunction plays a decisive role in the progression of type 2 diabetes. Retinol-binding protein 4 (RBP4) is a prominent adipokine in type 2 diabetes, although its effect on β-cell function remains elusive, and the underlying mechanisms are unknown. Here, we found that elevated circulating RBP4 levels were inversely correlated with pancreatic β-cell function in db/db mice across different glycemic stages. RBP4 directly suppressed glucose-stimulated insulin secretion (GSIS) in primary isolated islets and INS-1E cells in a dose- and time-dependent manner. RBP4 transgenic (RBP4-Tg) overexpressing mice showed a dynamic decrease of GSIS, which appeared as early as 8 weeks old, preceding the impairment of insulin sensitivity and glucose tolerance. Islets isolated from RBP4-Tg mice showed a significant decrease of GSIS. Mechanistically, we demonstrated that the stimulated by retinoic acid 6 (STRA6), RBP4’s only known specific membrane receptor, is expressed in β-cells and mediates the inhibitory effect of RBP4 on insulin synthesis through the Janus kinase 2/STAT1/ISL-1 pathway. Moreover, decreasing circulating RBP4 level could effectively restore β-cell dysfunction and ameliorate hyperglycemia in db/db mice. These observations revealed a role of RBP4 in pancreatic β-cell dysfunction, which provides new insight into the diabetogenic effect of RBP4.

1 August 2024 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
CHChun-Yu Hou
Chun-Yu Hou
YSYu-Hong Suo
Yu-Hong Suo
PLPan Lv
Pan Lv
HYHong-Feng Yuan
Hong-Feng Yuan
LZLina Zhao
Lina Zhao
XZXiao-Dong Zhang
Xiao-Dong Zhang

28 April 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
YCYunan Chen
Yunan Chen
XLXueyan Li
Xueyan Li
LSLei Su
Lei Su
QHQianrong Hu
Qianrong Hu
WLWenli Li
Wenli Li
LZLina Zhao
Lina Zhao
Cyanidin-3-O-glucoside (C3G) is a natural colorant with anti-diabetic properties, while its underlying mechanisms remain far from clear. Here, we investigated the protective role of C3G on palmitic acid (PA)-induced pancreatic beta cell dysfunction and further decipher its possible molecular mechanisms. Both primary isolated mouse islets and the INS-1E cell were used, and treated with a mixture of PA (0.5 mM) and C3G (12.5 µM, 25 µM, 50 µM) for different durations (12, 24, 48 h). We found that C3G could dose-dependently ameliorate beta cell secretory function and further alleviate cell apoptosis. Mechanistically, the primary role of the PKR-like ER kinase (PERK) endoplasmic reticulum (ER) stress pathway was detected by RNA sequencing, and the PERK-pathway-related protein expression, especially the pro-apoptotic marker C/EBP homologous protein (CHOP) expression, was significantly downregulated by C3G treatment. The critical role of CHOP in mediating the protective effect of C3G was further validated by small interfering RNA. Conclusively, C3G could ameliorate PA-induced pancreatic beta cell dysfunction targeting the CHOP-related ER stress pathway, which might be used as a nutritional intervention for the preservation of beta cell dysfunction in type 2 diabetes mellitus.

7 April 2020 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
RHRong Huang
Rong Huang
SYSongping Yin
Songping Yin
YYYongxin Ye
Yongxin Ye
NCNixuan Chen
Nixuan Chen
SLShiyun Luo
Shiyun Luo
LZLina Zhao
Lina Zhao
OBJECTIVE: The aim of this study was to examine the association of circulating retinol-binding protein 4 (RBP4) levels with β-cell function across the spectrum of glucose tolerance from normal to overt type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 291 subjects aged 35–60 years with normal glucose tolerance (NGT), newly diagnosed impaired fasting glucose or glucose tolerance (IFG/IGT), or type 2 diabetes were screened by a standard 2-h oral glucose tolerance test (OGTT) with the use of traditional measures to evaluate β-cell function. From these participants, 74 subjects were recruited for an oral minimal model test, and β-cell function was assessed with model-derived indices. Circulating RBP4 levels were measured by a commercially available ELISA kit. RESULTS: Circulating RBP4 levels were significantly and inversely correlated with β-cell function indicated by the Stumvoll first-phase and second-phase insulin secretion indices, but not with HOMA of β-cell function, calculated from the 2-h OGTT in 291 subjects across the spectrum of glycemia. The inverse association was also observed in subjects involved in the oral minimal model test with β-cell function assessed by both direct measures and model-derived measures, after adjustment for potential confounders. Moreover, RBP4 emerged as an independent factor of the disposition index-total insulin secretion. CONCLUSIONS: Circulating RBP4 levels are inversely and independently correlated with β-cell function across the spectrum of glycemia, providing another possible explanation of the linkage between RBP4 and the pathogenesis of type 2 diabetes.

28 November 2021 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
XGXiuwen Geng
Xiuwen Geng
JJJiajun Ji
Jiajun Ji
YLYuanhua Liu
Yuanhua Liu
XLXueyan Li
Xueyan Li
YCYunan Chen
Yunan Chen
LZLina Zhao
Lina Zhao